Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study

Pal Andre Holme, Lone Hvitfeldt Poulsen, Claudia Tueckmantel, Maria Teresa Alvarez Roman, Raimondo De Cristofaro

Blood (2021) 138 (Supplement 1): 4915.

https://doi.org/10.1182/blood-2021-144804

Published: 2021

Journal Articles

Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)

Galina Tsykunova, Pal André Holme, Hoa Thi Tuyet Tran, Tor Henrik Anderson Tvedt, Ludvig Andre Munthe, Marc Michel, Henrik Frederiksen, James B Bussel, David J. Kuter, Waleed Ghanima

Blood (2021) 138 (Supplement 1): 2088.

https://doi.org/10.1182/blood-2021-151410

Published: 2021

Journal Articles

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Waleed Ghanima, MD PhD, Marc Michel, Abderrahim Khelif, Bernadette Darne, Pal André Holme, PhDMD

Blood (2019) 134 (Supplement_1): 2358.

https://doi.org/10.1182/blood-2019-126975

Published: 2019

Journal Articles

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

Lamya Garabet, Pal André Holme, PhDMD, Bernadette Darne, Abderrahim Khelif, Tor Henrik Anderson Tvedt, MD, Marc Michel, Waleed Ghanima, MD PhD

Blood (2019) 134 (Supplement_1): 4892.

https://doi.org/10.1182/blood-2019-126974

Published: 2019

Journal Articles

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Mark T. Reding, MD, Lone Hvitfeldt Poulsen, Liu Tian, Dr, Pal André Holme, PhD MD

Blood (2018) 132 (Supplement 1): 2492.

https://doi.org/10.1182/blood-2018-99-114659

Published: 2018

Journal Articles

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Natasha Amrita Satkunam, MBBS, MSc, Johnny Mahlangu, MD, Christoph Bidlingmaier, MD PD, Dr. MD, Maria Eva Mingot-Castellano, PhD, Meera B. Chitlur, MD, Patrick F. Fogarty, MD, Adam Cuker, MD MS, Maria Elisa Mancuso, MD PhD, Pal André Holme, PhD MD, Julie Grabell, BA, CCRP, Wilma Hopman, MA, Prasad Mathew, MD, Paula D. James, MD

Blood (2016) 128 (22): 875.

https://doi.org/10.1182/blood.V128.22.875.875

Published: 2016

Journal Articles

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Ana Rosa Cid, MD, Carmen Escuriola, MD, Cedric R. Hermans, MD PhD MRCP, Pal André Holme, PhD MD, Claude Negrier, MD, Savita Rangarajan, Angiola Rocino, Jerzy Windyga, MD, Alessandro Gringeri, MD MSc, Roberto Crea, DVM, MSc

Blood (2016) 128 (22): 5038.

https://doi.org/10.1182/blood.V128.22.5038.5038

Published: 2016

Journal Articles

Renal Status and Hematuria in Older Patients with Hemophilia

Pal André Holme, PhDMD, Robert Campbell Tait, MD, Christophe Combescure, PhD, Erik Berntorp, MD PhD, Annarita Tagliaferri, Peter Staritz, MD, Roger E.G. Schutgens, MD PhD, Robert Klamroth, Natascha Marquardt, Stephan Rauchensteiner, Philippe De Moerloose, MD PhD

Blood (2015) 126 (23): 2290.

https://doi.org/10.1182/blood.V126.23.2290.2290

Published: 2015

Journal Articles

Multicentric Study Evaluating Venous Thrombosis Among Patients with Haemophilia Undergoing Major Orthopaedic Surgery

Cedric R. Hermans, MD PhD, Catherine Lambert, MD, Pal André Holme, PhDMD

Blood (2014) 124 (21): 1496.

https://doi.org/10.1182/blood.V124.21.1496.1496

Published: 2014

Journal Articles

Rituximab As Second Line Treatment For Adult Immune Thrombocytopenia (ITP): A Multicentre, Randomized, Double Blind, Placebo-Controlled Study – The Ritp Study (NCT00344149)

Waleed Ghanima, MD, PhD, Abderrahim Khelif, Neila Benromdhan, MD, Anders Waage, MD, PhD, Geir E. Tjonnfjord, MD, PhD, Marc Michel, Darne Bernadette, MD, Johannes Kahrs, MD, Pål Andre Holme, MD, PhD

Blood (2013) 122 (21): 449.

https://doi.org/10.1182/blood.V122.21.449.449

Published: 2013

NARROW

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study

Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Renal Status and Hematuria in Older Patients with Hemophilia

Multicentric Study Evaluating Venous Thrombosis Among Patients with Haemophilia Undergoing Major Orthopaedic Surgery

Rituximab As Second Line Treatment For Adult Immune Thrombocytopenia (ITP): A Multicentre, Randomized, Double Blind, Placebo-Controlled Study – The Ritp Study (NCT00344149)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only